Researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells – employing a strategy that turns the protein’s own molecular machinations against it.
This is Rani George, MD, PhD, of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, in her lab
Credit: Sam Ogden, Dana-Farber/Boston Children’s
The co-authors of the study are Eugenio Marco, PhD, Camilla Christensen, PhD, Tinghu Zhang, PhD, Clark Hatheway, Bandana Sharma, PhD, Caleb Yeung, Abigail Altabef, Kwok-Kin Wong, MD, PhD, Guo-Cheng Yuan, PhD, and Nathanael Gray, PhD, of Dana-Farber; Nicholas Kwiatkowski, PhD, Brian Abraham, PhD, and Richard Young, PhD, of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology; and Antonio Perez-Atayde, PhD, of Boston Children’s Hospital.
The study was supported by grants from the National Institutes of Health, American Cancer Society, U.S. Department of Defense, and Friends for Life Neuroblastoma Foundation.